Japan’s Chuikyo Reveals NHI Prices For New Drugs From BMS, Ajinomoto, Novo Nordisk And Others
This article was originally published in PharmAsia News
Executive Summary
Sanofi gains 5% price premium for antihistamine Telfast as Japan is hit with strong hay fever season.
You may also be interested in...
Novo Nordisk Dismayed By “Complete Response” Letter For Insulin Degludec
FDA is requesting data from a dedicated cardiovascular outcomes trial before approving the ultra-long-acting insulins Tresiba and Ryzodeg. News of the regulatory setback caused a 13% drop in the company’s stock price on Feb. 11.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.